Modality
Vaccine
MOA
FGFRi
Target
MALT1
Pathway
PI3K/AKT
Gastric CaPBC
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
Jul 2017
→ Apr 2031
Phase 2Current
NCT07599893
2,744 pts·Gastric Ca
2020-11→2031-04·Terminated
NCT05050138
1,107 pts·PBC
2017-07→2029-10·Active
3,851 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-10-103.5y awayPh2 Data· PBC
2031-04-035.0y awayPh2 Data· Gastric Ca
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Active
P2
Termina…
Catalysts
Ph2 Data
2029-10-10 · 3.5y away
PBC
Ph2 Data
2031-04-03 · 5.0y away
Gastric Ca
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07599893 | Phase 2 | Gastric Ca | Terminated | 2744 | ORR |
| NCT05050138 | Phase 2 | PBC | Active | 1107 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| ION-8812 | Ionis | Phase 1 | MALT1 |